Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 24, 2023

BUY
$63.71 - $70.74 $254 - $282
4 Added 0.12%
3,381 $216,000
Q1 2023

May 11, 2023

SELL
$65.71 - $74.53 $22,209 - $25,191
-338 Reduced 9.1%
3,377 $234,000
Q4 2022

Jan 18, 2023

BUY
$68.48 - $81.09 $205 - $243
3 Added 0.08%
3,715 $0
Q3 2022

Oct 14, 2022

SELL
$0.13 - $76.84 $13 - $7,991
-104 Reduced 2.73%
3,712 $264,000
Q2 2022

Jul 27, 2022

SELL
$72.62 - $79.98 $7,697 - $8,477
-106 Reduced 2.7%
3,816 $294,000
Q1 2022

Apr 14, 2022

BUY
$61.48 - $73.72 $241,124 - $289,129
3,922 New
3,922 $286,000
Q4 2021

Jan 18, 2022

SELL
$53.63 - $62.52 $247,824 - $288,904
-4,621 Closed
0 $0
Q3 2021

Oct 18, 2021

SELL
$59.17 - $69.31 $1,597 - $1,871
-27 Reduced 0.58%
4,621 $273,000
Q2 2021

Aug 03, 2021

SELL
$61.91 - $67.42 $7,305 - $7,955
-118 Reduced 2.48%
4,648 $311,000
Q1 2021

Apr 27, 2021

SELL
$59.34 - $66.74 $316,460 - $355,924
-5,333 Reduced 52.81%
4,766 $301,000
Q4 2020

Jan 29, 2021

BUY
$57.74 - $65.43 $205,207 - $232,538
3,554 Added 54.3%
10,099 $626,000
Q3 2020

Oct 20, 2020

BUY
$57.43 - $63.64 $95,850 - $106,215
1,669 Added 34.23%
6,545 $395,000
Q2 2020

Jul 31, 2020

BUY
$54.82 - $64.09 $267,302 - $312,502
4,876 New
4,876 $287,000
Q1 2020

May 04, 2020

SELL
$46.4 - $67.43 $161,704 - $234,993
-3,485 Closed
0 $0
Q4 2019

Feb 21, 2020

BUY
$49.21 - $64.19 $171,496 - $223,702
3,485 New
3,485 $224,000
Q3 2018

Oct 19, 2018

SELL
$55.19 - $62.25 $286,877 - $323,575
-5,198 Closed
0 $0
Q2 2018

Jul 31, 2018

BUY
$50.53 - $62.98 $1,718 - $2,141
34 Added 0.66%
5,198 $288,000
Q1 2018

Apr 16, 2018

BUY
$59.92 - $68.98 $1,557 - $1,793
26 Added 0.51%
5,164 $327,000
Q4 2017

Feb 09, 2018

BUY
$59.94 - $65.35 $307,971 - $335,768
5,138
5,138 $315,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track De Dora Capital, Inc. Portfolio

Follow De Dora Capital, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of De Dora Capital, Inc., based on Form 13F filings with the SEC.

News

Stay updated on De Dora Capital, Inc. with notifications on news.